Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...1011121314151617181920...5960»
  • ||||||||||  clomifene citrate / Generic mfg.
    Review, Journal:  An acromegaly case treated with clomiphene citrate: add-on treatment in primary medical therapy. (Pubmed Central) -  Mar 15, 2023   
    Biochemical control is not always achieved with somatostatin receptor ligands and dopamine agonists in the treatment of acromegaly. Therefore, we support the use of clomiphene citrate (CC) as a cost-effective oral add-on treatment option in selected hypogonadal acromegaly cases.
  • ||||||||||  Journal:  High chitotriosidase and AGE levels in acromegaly: a case-control study. (Pubmed Central) -  Mar 15, 2023   
    Serum CHITO, AGE, and hsCRP levels in acromegalic patients were significantly increased. It may be important to evaluate CHITO, AGE, and hsCRP levels in acromegalic patients who are already under cardiometabolic surveillance due to risk of developing cardiovascular disease.
  • ||||||||||  Journal:  Growth hormone signaling in liver diseases: Therapeutic potentials and controversies. (Pubmed Central) -  Mar 14, 2023   
    The functional roles of GH/IGF1 signaling and the effects of agonists/antagonists targeting this signaling may differ depending on the liver injury or animal models. This review summarizes current controversial studies of GH/IGF1 signaling in liver diseases and discusses therapeutic potentials of GH therapy.
  • ||||||||||  octreotide injection (SYHX2008) / CSPC Pharma
    Enrollment open:  A Single-dose Study of Octreotide Injection in Healthy Adult Subjects (clinicaltrials.gov) -  Mar 14, 2023   
    P1,  N=56, Recruiting, 
    This review summarizes current controversial studies of GH/IGF1 signaling in liver diseases and discusses therapeutic potentials of GH therapy. Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  The science behind the relations among cancer, height, growth patterns and growth hormone axis. (Pubmed Central) -  Mar 13, 2023   
    In animal and human models, genetic defects associated with GH deficiency or resistance are associated with protection from tumor development, while risk of malignancies in acromegaly or in patients exposed to recombinant GH therapy has long been a matter of concern and scrutiny. In this review, we present a narrative and historical review covering the potential relations among height, growth patterns, GH axis and cancer.
  • ||||||||||  Journal:  Survivin: a potential marker of resistance to somatostatin receptor ligands. (Pubmed Central) -  Mar 13, 2023   
    In this review, we present a narrative and historical review covering the potential relations among height, growth patterns, GH axis and cancer. This study suggests that low survivin expression is predictive of resistance to fg-SRL in somatotropinomas, but not of tumor invasiveness.
  • ||||||||||  Journal:  Histological Manifestations of Diabetic Kidney Disease and its Relationship with Insulin Resistance. (Pubmed Central) -  Mar 9, 2023   
    Elevated levels of IGF x ULN before radiosurgery and invasion of the cavernous sinus by the tumor could be predictors of biochemical non-remission of acromegaly. Several heterogeneous conditions that share the occurrence of insulin resistance, such as aging, obesity, acromegaly, lipodystrophy, cystic fibrosis, insulin receptor dysfunction, and Alstr
  • ||||||||||  Review, Journal:  Pituitary and SARS CoV-2: An unremitting conundrum. (Pubmed Central) -  Mar 7, 2023   
    This review summarizes data analysis to date on the possible effects of COVID-19 and COVID-19 vaccination on patients with normal pituitary function and patients with known pituitary pathology. Though clinical systems were significantly affected, it seems there is no overall loss of biochemical control in patients with certain pituitary pathologies.
  • ||||||||||  Journal:  Calvaria thickening in acromegaly. (Pubmed Central) -  Mar 6, 2023   
    Though clinical systems were significantly affected, it seems there is no overall loss of biochemical control in patients with certain pituitary pathologies. No abstract available
  • ||||||||||  paltusotine (CRN00808) / Crinetics
    Journal:  Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine. (Pubmed Central) -  Feb 27, 2023   
    We then perform cryo-electron microscopy analysis of SSTR2-Gi complexes to determine how the drugs activate SSTR2 in a selective manner. In this work, we decipher the mechanism of ligand recognition, subtype selectivity and signal bias property of SSTR2 sensing octreotide and paltusotine, which may aid in designing therapeutic drugs with specific pharmacological profiles against neuroendocrine tumors.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  Diet in the Management of Acromegaly (clinicaltrials.gov) -  Feb 8, 2023   
    P=N/A,  N=9, Not yet recruiting, 
    This study highlights the importance of correct model system selection for cell transcriptomic profiling and data interpretation that could be achieved in future by incorporating NGS methods and detailed cell omics profiling in PitNET model research. Trial completion date: Jun 2023 --> Mar 2024 | Initiation date: Aug 2022 --> Mar 2023 | Trial primary completion date: Jun 2023 --> Mar 2024
  • ||||||||||  Review, Journal:  Growth hormone and gastrointestinal malignancy: An intriguing link. (Pubmed Central) -  Feb 7, 2023   
    Recommendations for further follow-up colonoscopy differ but broadly, the guidelines agree that it depends on the findings at first colonoscopy and state of remission of GH excess. Regarding the concern about the risk of colorectal cancers in patients receiving recombinant GH therapy, most cohort studies do not show an increased risk.
  • ||||||||||  Retrospective data, Journal:  Polycystic ovary syndrome preceding the diagnosis of acromegaly: a retrospective study in 97 reproductive-aged women. (Pubmed Central) -  Feb 2, 2023   
    Our data demonstrate a high prevalence of signs and symptoms of PCOS in reproductive-aged women with acromegaly and a longer time to diagnosis in women who meet the clinical criteria for PCOS. As screening for acromegaly is relatively simple and done with measurement of a random, non-fasting IGF-1 level that can be drawn at any time during the menstrual cycle, screening patients with PCOS for acromegaly may lessen the delay in diagnosis for reproductive-aged women with this disease.
  • ||||||||||  CSF leak in endoscopic pituitary surgery is associated with increased risk of diabetes insipidus () -  Jan 25, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_118;    
    The association with younger age and increased risk of CSF leak may reflect a more aggressive surgical attempt at gross total resection, which in itself might predispose to DI, as may acromegaly. Intraoperative CSF leak predisposes to a diagnosis of DI in our series and should be a flag for increased vigilance for this complication in the perioperative period, in addition to the known risk of meningitis.
  • ||||||||||  Journal:  Short-term and long-term remission after endoscopic transnasal adenomectomy in patients with acromegaly (Pubmed Central) -  Jan 24, 2023   
    Rates of short-term and long-term remission after endoscopic transsphenoidal adenomectomy in our cohort is 79,5% и 61,4%, respectively, and is comparable with literature data for expert pituitary centers. Preoperative GH shows potential value in predicting the long-term remission of acromegaly, but further studies in a larger sample are needed to obtain more accurate cut-off values.
  • ||||||||||  paltusotine (CRN00808) / Crinetics
    Journal:  Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist. (Pubmed Central) -  Jan 20, 2023   
    In pharmacodynamic studies, compound 22 dose-dependently suppressed growth hormone (GH) secretion induced by an exogenous growth-hormone-releasing hormone (GHRH) challenge in both male and female rats following a single oral dose and suppressed IGF-1 levels with repeated oral administration in both rats and dogs. To the best of our knowledge, compound 22 is the first non-peptide SST2 agonist to advance to human clinical trials and is currently in Phase 3 trials in acromegaly patients and a Phase 2 trial in neuroendocrine tumor patients suffering from carcinoid syndrome.
  • ||||||||||  Journal:  Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. (Pubmed Central) -  Jan 19, 2023   
    To the best of our knowledge, compound 22 is the first non-peptide SST2 agonist to advance to human clinical trials and is currently in Phase 3 trials in acromegaly patients and a Phase 2 trial in neuroendocrine tumor patients suffering from carcinoid syndrome. GH status is a significant modulator of body composition and insulin sensitivity.GH excess reduces total fat mass and intrahepatic lipid content together with induction of insulin resistance.The data support the notion that GH-induced insulin resistance is unassociated with hepatic lipid accumulation.
  • ||||||||||  Signifor (pasireotide) / Recordati
    Journal:  Resistance of neuroendocrine tumours to somatostatin analogs. (Pubmed Central) -  Jan 19, 2023   
    We explore mechanisms used to counteract the resistance to SSAs using higher doses or more frequent mode of administration of SSAs and/or combination treatments. There is considerable heterogeneity in the development of resistance to SSAs that is tumor-specific necessitating the delineation of the underlying pathophysiological processes to further expand their therapeutic applications.
  • ||||||||||  Journal:  A study of acromegaly-associated headache with somatostatin analgesia. (Pubmed Central) -  Jan 13, 2023   
    Further studies are needed to understand the mechanisms, markers and tumour tissue characteristics of acromegaly-related headache. Until then, this publication serves to provide the clinical characteristics as a reference point for further study.